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Original article 
18F-FDG-PET and MRI in patients 
with malignancies of the liver  
and pancreas 
Accuracy of retrospective multimodality image 
registration by using the CT-component of PET/CT  
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Summary 
Purpose: To evaluate the accuracy of retrospec-
tive rigid image registration and fusion be-
tween F-18 fluorodeoxyglucose positron 
emission tomography (FDG-PET) and magnetic 
resonance imaging (MRI) of the upper ab-
domen. Patients, material, methods: Image 
fusion of PET and MRI was performed in 30 pa-
tients with suspected malignancy of the liver or 
pancreas. Using a commercially available 
image fusion tool capable of rigid manual 
point-based registration, PET-Images were 
retrospectively registered and fused by match-
ing eight homologous points in the 3D spoiled 
gradient echo (GRE) MRI sequences acquired in 
portal venous phase and in the CT-component 
of PET/CT. Two separate observers (R1, R2) as-
sessed accuracy of image registration by deter-
mining the distances in the x-, y- and z-axis as 
well as the absolute distance between ana-
tomical landmarks which differed from the 
landmarks chosen for registration. Quality of 
fusion was graded using a three point grading 
scale (1 poorly fused; 2 satisfactory fused; 3 cor-
rectly fused) and compared to hybrid PET/CT 
fusion. Results: Mean time of registration per 
tomographie (FDG-PET) und Magnetreso-
nanztomographie (MRI) im Oberbauch. Pa-
tienten, Material, Methoden: Die Bildfusion 
von PET und MRI wurde in 30 Patienten mit 
Verdacht auf maligne Leber- oder Pankreaslä-
sionen durchgeführt. Mit Hilfe einer frei er-
hältlichen Software, welche die rigide, manu-
elle und punktbasierte Registrierung ermög-
licht, wurden PET-Bilder mittels acht homolo-
ger Punkten einer 3D Gradienten -
echosequenz der MRI sowie der CT-Kom-
ponente der PET/CT registriert und fusioniert. 
Zwei Radiologen (R1, R2) evaluierten die Ge-
nauigkeit der Bildregistrierung und -fusion 
durch Bestimmung der Distanzen in der x-, y- 
und z-Achse sowie durch Bestimmung der ab-
soluten Distanz zwischen anatomischen 
Landmarken welche sich von den Landmar-
ken, welche zur Registrierung benutzt wurden 
unterschieden. Die Qualität der Fusion wurde 
subjektiv mittels einer Drei-Punkte-Skala be-
wertet (1, ungenügend fusioniert; 2 zufrieden-
stellend fusioniert; 3 korrekt fusioniert) und 
mit der Hybrid PET/CT Fusion verglichen. Re-
sultate: Die durchschnittliche Zeit, welche zur 
Fusion pro Patient aufgewendet wurde betrug 
weniger als zwei Minuten. Die Messung der 
Distanzen zwischen homologen Punkten 
zeigte Registrierungsfehler zwischen 2.4–6.3 
mm in x-Richtung: Durchschnitt 3.6 mm (R1); 
4.6 mm (R2), 2.3–9.3 mm in y-Richtung (5.1 
mm; 5.5 mm) und 3.3–12mm in z-Richtung 
(5.9 mm; 5.9 mm). Der durchschnittliche Re-
gistrierungsfehler der absoluten Distanz zwi-
schen zwei homologen Punkten betrug 
6.0–16.8 mm (9.9 mm; 10.6 mm). In der sub-
jektiven, visuellen Auswertung der Fusions-
genauigkeit zeigten die meisten Fusionen ein 
zufriedenstellendes oder korrektes Resultat: 
R1, R2: Grad 3, 11/30 (36.7%), 22/30 (73.3%); 
patient was less than 2 minutes. Objective regis-
tration assessment showed errors between 
2.4–6.3 mm in x-axis: mean 3.6 mm (R1); 4.6 
mm (R2), 2.3–9.3 mm in y-axis (mean 5.1 mm; 
5.5 mm) and 3.3–12.0 mm in z-axis (mean 5.9 
mm; 5.9 mm.) The mean error in absolute dis-
tance between points was 6.0–16.8 mm (mean 
9.9 mm; 10.6 mm). In visual assessment, most 
fusions were graded to be satisfactory or cor-
rectly fused: R1, R2: grade 3, 11/30 (36.7%), 
22/30 (73.3%); grade 2, 13/30 (43.3%), 8/30 
(26.7%); grade 1, 6/30 (20%), 0/30 (0%). 
Fusions were mostly comparable to hybrid PET/
CT fusions. All of the fusions were defined as 
diagnostically relevant by both observers. Con-
clusion: Retrospective rigid image fusion of FDG-
PET and MRI of the upper abdomen using the 
CT-component of PET/CT for registration is feas-
ible without adaptation in image acquisition 
protocols and shows sub-centimeter regis-
tration errors in most cases. 
 
Schlüsselwörter 
Magnetresonanztomographie, Positronenemis-
sionstomographie, PET/MR, Bildfusion, PET/CT 
Zusammenfassung 
Ziel: Evaluation der Genauigkeit der retrospek-
tiven rigiden Bildregistrierung und -fusion von 
18F-Fluordeoxyglukose Positronenemissions-
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Computed tomography (CT) and mag-
netic resonance imaging (MRI) are cur-
rently considered as the backbone for de-
tection and characterization of malignan-
cies of the liver and pancreas. Both imaging 
modalities provide accurate information 
with regard to anatomical location and size 
of the lesions and are helpful (1) in  
● prediction of lesion malignancy,  
● staging and restaging; 
● assessment of therapeutic response and 
● preoperative planning.  
 
Over the last decade, positron emission to-
mography using 18F-fluorodeoxyglucose 
(FDG-PET) and in particular PET/CT have 
shown to be valuable in staging of primary 
and secondary tumours of the liver and 
pancreas, and especially in the assessment 
of distant metastases and tumour response 
(2–9). With the availability of PET/CT, 
fusion of detailed morphology obtained 
from CT with functional information from 
PET into a single image using an integrated 
device has shown to provide new possibil-
ities for diagnosis and therapy. Fur-
thermore, the fusion of PET and CT images 
into a single image has been shown to be 
more accurate in tumour staging than PET 
or CT alone and even more than PET and 
CT images viewed side by side (10–13). 
Based on its inherent soft-tissue 
contrast, MRI provides several advantages 
over CT in evaluating malignancies of the 
liver as well as of the pancreas. In addition, 
MRI offers the possibility to use tissue-spe-
cific contrast agents which may be benefi-
cial for detection and characterization of 
liver neoplasms. It has been shown that 
MRI in combination with standard gado-
linium based extracellular contrast agents 
and/or with liver specific contrast agents is 
superior to contrast enhanced CT for im-
aging various primary liver neoplasms and 
metastases (14–17). Although MRI in com-
bination with liver specific contrast agents 
provides some functional information, it 
may be desirable to combine MRI with 
functional PET data, especially regarding 
therapy response assessment. Whereas 
PET/CT hybrid systems for body appli-
cations are already commercially available, 
hybrid PET/MRI scanners are still under 
development and as yet not commercially 
available (18, 19).  
Therefore, the only way to currently per-
form registration of FDG PET and MRI 
data is by software based image registration 
and fusion of the separately acquired data 
sets. Reports on PET/MRI image fusion in 
the upper abdomen are rare and to the best 
of our knowledge there are only two studies 
addressing feasibility of imaging fusion be-
tween PET and MRI in this body region 
(20, 21). Whereas Lemke et al. (20) re-
ported on feasibility and impact of imaging 
fusion between FDG PET and MRI in vari-
ous organ systems including the upper ab-
domen, Ruf et al. (21) reported on the im-
pact of FDG-PET/MRI fusion in the detec-
tion of pancreatic cancer. However, neither 
study quantitatively investigated the accu-
racy of image registration between PET 
and MRI.  
The purpose of this study was to evalu-
ate the accuracy of interactive, retrospec-
tive, point-based, rigid image registration 
and fusion between standard clinical PET 
and MRI datasets in patients with sus-
pected or confirmed malignancies of the 
liver or pancreas.  
Patients, material, methods 
This study was approved by the institu-
tional ethical review board. Informed pa-
tient consent was waived for this retrospec-
tive evaluation. 
Patients  
Fulfilling the following inclusion criteria 30 
patients were included:  
● contrast enhanced MRI imaging of the 
upper abdomen within 30 days of the 
PET/CT scan, 
● suspected or confirmed malignancy of 
liver or pancreas,  
● no surgery, chemo- or radiotherapy be-
tween acquisition of PET/CT and MRI.  
 
The study group consisted of 15 men and 
15 women with an age range between 28 
and 82 years (mean 61.2 ± 14). The mean 
time between MRI and PET/CT was 
11.3 ± 9.2 days, ranging from 0 to 30 days. 
MRI and PET/CT scanning were ordered 
primarily for staging and preoperative 
planning purposes. The 30 patients in-
cluded 4 patients with carcinoma of the 
pancreas, 9 with primary liver tumours (5 
cholangiocellular carcinomas, 2 haem-
angioendothelioma, 2 focal nodular hyper-
plasia), 15 patients with liver metastasis 
(origin of metastases: 5 gastrointestinal 
carcinoma, 2 oropharyngeal carcinoma, 2 
melanoma, 2 lung cancer, 1 neuroendo-
crine tumour of the pancreas, 1 cholangio-
cellular carcinoma, 1 hepatocellular carci-
noma, 1 breast cancer). In two patients, 
liver metastases were clinically suspected 
but were ruled out by imaging follow-up.  
Fig. 1 The field of view (FOV) was chosen according to the patient's individual body size (a). In axial 
direction (b), the FOV was chosen to include the area from the liver dome down to the lower poles of the 
kidneys. 
Grad 2, 13/30 (43.3%), 8/30 (26.7%); Grad 
1, 6/30 (20%), 0/30 (0%). Die meisten Fusio-
nen waren subjektiv vergleichbar mit denen 
des Hybrid PET/CT Systems. Sämtliche Fusio-
nen wurden von beiden Radiologen als diag-
nostisch bewertet. Schlussfolgerung: Die re-
trospektive, rigide Bildfusion von FDG-PET 
und MRI im Oberbauch durch Benutzung der 
CT-Komponente der PET/CT für die Registrie-
rung ist ohne Anpassung der Akquisitions-
protokolle durchführbar und zeigt in den 
meisten Fällen Registrierungsfehler im Sub-
Zentimeter-Bereich.  
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Data acquisition 
PET/CT- and MRI-images were acquired 
separately without taking special prerequi-
sites with regard to the planned image fusion. 
PET/CT 
All data were acquired on either of two 
combined PET/CT in-line systems (Dis-
covery ST or Discovery RX; GE Health-
care). These dedicated systems integrate a 
PET scanner with a multislice helical CT 
scanner (64 slice VCT / 16 slice Lightspeed 
16; GE Healthcare) and permit the acquisi-
tion of coregistered CT and PET images in 
a single session. 
The patients fasted for at least 4 h before 
scanning, which started approximately 60 
min after the injection of 370–400 MBq of 
18F-FDG and the glucose level (range, 
80–120 mg/dl; 4.4–6.7 mmol/l) was 
measured. Patients with elevated glucose 
levels were rescheduled, prepared with in-
sulin, and scanned when they had normal 
glucose levels. Patients were examined in 
the supine position. Initially, a low dose CT 
scan was acquired starting from the level of 
the head using the following parameters: 40 
mAs, 140 kV, 0.5 s/tube rotation, a slice 
thickness of 4.25 mm, a scan length of 867 
mm, and a data acquisition time of 22.5 s. 
The CT scan was acquired during breath 
holding in the normal expiratory position. 
The low dose CT data were used for attenu-
ation correction, lesion localization and CT 
lesion characterization. The images were 
reconstructed using a standard iterative al-
gorithm. Immediately after the CT acquisi-
tion, a PET emission scan was acquired 
with a time of 90 s to 3 min per cradle posi-
tion with a 1-slice overlap in 2-D or full 3-D 
reconstruction mode (matrix 128 × 128). 
The 8–9 cradle positions starting from the 
head and continuing to the knees resulted 
in an acquisition time of approximately 
12–27 min. PET/CT was performed ac-
cording to the recently published pro-
cedure guideline for tumour imaging with 
18F-FDG PET/CT (22).  
MRI 
All MR imaging was performed on a 1.5 T 
MR scanner (Signa EchoSpeed EXCITE® 
HD or HDx, GE Healthcare, Waukesha, 
Wisconsin, USA) using an 8-channel ante-
roposterior phased-array surface coil 
which was placed around the individual 
and covered the entire liver. The field of 
view (FOV) was chosen according to the 
patient’s individual body size. In transverse 
direction, the FOV was chosen to include 
the area from the liver dome down to the 
lower poles of the kidneys (Fig. 1). Im-
aging protocol included an unenhanced 
two-dimensional T2-weighted breathhold 
single shot fast spin echo sequence (SSFSE) 
Fig. 2 Patient (age: 30 years) with intrahepatic cholangiocellular carcino-
ma Landmarks A and B (for determination of the upper pole of right kidney 
(circles)) are manually determined before image registration in CT (a) and 
contrast-enhanced MR image (b). Afterwards, point A is copied and pasted 
(A‘) to the PET-component of hybrid PET/CT (c). Rigid point-based software 
registration is then realized between PET and ceMRI based on these land-
marks. (A‘ and B) 
Fig. 3 Anatomical landmarks used for data validation  
a) most anteriorly (ventrally) located point of the liver surface (AL); b) point on the surface of the liver 
which was located most laterally at the level of the left portal vein (LL); c) right adrenal (RA);  
d) center of the smallest clearly detectable liver lesion if present (LE); e) origin of the left portal vein 
(PV); f) celiac trunk at the level of the aortic origin (TC) 
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in coronal plane, a transverse T2-weighted 
fat suppressed respiratory-triggered fast 
spin echo sequence (FSE) and a transverse 
T1-weighted breathhold fast spoiled gradi-
ent-recalled echo sequence (FSPGR) in-
phase and out-of-phase. In patients with 
suspected cholangiocarcinoma or patients 
with visible bile duct dilation in the other 
unenhanced sequences MR cholangi-
ography (MRC) using a three dimensional 
3D fast spin recovery fast spin echo se-
quence (FRFSE) was performed. 
Following acquisition of the unenhanced 
sequences contrast-enhanced dynamic MR 
imaging was performed following intra-
venous administration of a standard dose 
(0.1 mmol/kg bodyweight) of either gadobu-
trol (Gadovist, Bayer-Schering AG) or gado-
linium-EOB DTPA (Primovist, Bayer-Scher-
ing AG). For dynamic contrast enhanced im-
aging, a parallel three-dimensional (3D) 
spoiled gradient echo (GRE) sequence 
(LAVA (Liver Acquisition with Volume Ac-
celeration), version 12.0M4; GE Healthcare) 
was performed during a breath hold in trans-
verse plane with a nominal measured voxel 
dimension of 1.5 × 1.5 × 4.0 mm3 in acquisi-
tion along the frequency-encoding times 
phase-encoding times section-encoding di-
rection, and an interpolated reconstructed 
voxel dimension of 0.75 × 0.75 × 2.0 mm3. 
Dynamic contrast-enhanced parallel GRE 
imaging was performed in the arterial (20 s 
after injection), portal venous (60–80 s after 
injection) and hepatic phase (240 s after in-
jection). Comparable to previous studies 
(20, 21), the portal venous phase was chosen 
for image registration with the CT-com-
ponent of PET/CT because this sequence 
best demonstrates anatomic detail.  
Image registration 
MRI and PET/CT data were transferred in 
DICOM format to a workstation running 
Tab. 1 Overview of PET / MRI registration errors separated by observer and anatomical landmark 
anatomical 
landmark 
measurement 
direction 
F1/F2 observer 1 
mean max SD 
AL x-axis  4.65 /  2.49 27.80 / 27.00 5.35 /  7.29 
y-axis  8.27 /  6.81 23.80 / 30.20 5.88 /  8.29 
z-axis  6.60 /  6.63 18.00 / 28.00 3.68 /  7.33 
dist 13.31 / 11.19 30.80 / 39.79 6.95 / 10.55 
z-axis  3.73 /  5.11 10.00 / 14.00 2.35 /  4.02 
dist  7.94 /  7.23 15.86 / 18.94 3.06 /  4.31 
LE x-axis  6.31 /  3.43 19.50 / 15.10 4.71 /  4.85 
y-axis  4.44 /  2.29 11.00 / 12.00 3.20 /  4.16 
z-axis  6.14 /  3.25 26.00 / 10.00 6.71 /  2.91 
dist 11.25 /  5.97 31.00 / 15.97 7.53 /  4.58 
all measurements in mm; AL: anterior liver border; LL: lateral liver border; TC: celiac trunk; PV: left portal vein; RA: right adrenal gland; LE: liver lesion; 
dist: Euclidean distance; F1: registration performed by physician 1; F2: registration performed by physician 2 
SD 
3.41 / 2.47 
6.25 / 6.24 
5.35 / 5.74 
5.83 / 6.96 
3.11 / 3.45 
3.18 / 3.55 
3.90 / 2.46 
2.67 / 2.29 
6.78 / 2.62 
6.10 / 3.09 
F1/F2 observer 2 
mean 
 4.94 /  7.93 
 7.44 /  7.97 
 4.68 /  9.21 
11.36 / 16.53 
 4.05 /  6.05 
 7.28 /  9.09 
 5.86 /  4.77 
 3.96 /  3.69 
 4.84 /  4.37 
 9.65 /  9.03 
min 
0.00 / 0.10 
0.00 / 0.70 
1.50 / 0.00 
2.81 / 3.95 
2.00 / 0.00 
2.53 / 3.32 
0.60 / 0.10 
0.00 / 0.00 
0.00 / 2.00 
2.19 / 3.68 
z-axis  6.59 / 12.02 5.35 / 8.98 11.51 / 10.46 0.00 / 0.00 32.10 / 30.00 8.52 /  7.55 
dist 12.04 / 14.89 6.09 / 9.55 16.76 / 14.50 6.45 / 3.60 39.82 / 42.39 9.14 /  8.69 
PV x-axis  3.37 /  2.58 3.38 / 2.32  3.18 /  3.82 0.00 / 0.00 10.80 / 15.50 2.65 /  3.72 
y-axis  5.00 /  4.19 3.95 / 3.18  3.89 /  4.95 0.30 / 1.00 12.00 / 8.70 2.87 /  2.20 
z-axis  5.52 /  6.11 3.77 / 6.05  3.69 /  4.38 0.00 / 0.00  8.10 / 14.00 2.46 /  3.74 
dist  9.42 /  8.89 4.30 / 5.82  7.26 /  8.75 2.09 / 3.27 12.22 / 18.12 2.66 /  3.69 
RA x-axis  3.63 /  2.36 2.82 / 2.76  3.41 /  3.86 0.40 / 1.00 15.20 / 13.60 3.13 /  2.91 
y-axis  4.68 /  2.93 2.65 / 2.40  3.60 /  3.81 0.00 / 0.00  9.40 / 11.90 2.55 /  3.35 
min 
0.30 / 0.00 
1.20 / 0.50 
0.00 / 0.00 
5.36 / 4.05 
0.00 / 0.00 
5.36 / 5.12 
0.00 / 0.00 
0.00 / 0.00 
0.00 / 0.00 
3.42 / 1.49 
0.00 / 0.00 
0.70 / 0.00 
0.00 / 0.00 
3.23 / 2.20 
0.60 / 1.00 
0.70 / 1.00 
0.00 / 0.00 
3.32 / 1.94 
max 
12.00 / 11.20 
28.80 / 27.30 
20.00 / 28.00 
31.08 / 29.95 
20.00 / 30.00 
32.90 / 36.43 
15.20 / 10.40 
13.00 / 11.60 
16.00 / 22.00 
19.98 / 24.98 
13.90 /  9.90 
10.70 /  8.50 
12.05 / 12.00 
16.03 / 13.75 
12.60 / 10.50 
12.30 / 10.00 
20.00 / 12.00 
26.14 / 12.38 
LL x-axis  4.39 /  3.96 0.00 / 0.10 10.80 / 12.70 2.88 / 3.08  4.03 /  5.76 0.10 / 1.40 17.10 / 14.70 3.87 /  3.42 
y-axis  5.34 /  2.71 0.40 / 0.00 17.70 / 10.20 4.77 / 2.30  3.75 /  5.65 0.00 / 0.90  9.40 / 21.50 2.64 /  3.99 
z-axis  5.42 /  5.77 0.00 / 0.00 20.05 / 32.00 5.11 / 6.27  4.01 /  5.25 0.00 / 0.00 14.00 / 16.00 3.39 /  4.21 
dist 10.27 /  8.34 2.72 / 1.12 23.84 / 33.06 5.26 / 6.35  7.90 / 10.62 2.09 / 2.76 22.22 / 26.18 4.13 /  4.94 
TC x-axis  4.05 /  2.32 0.00 / 0.00  8.20 /  7.70 2.36 / 2.03  4.10 /  3.68 0.50 / 0.00  8.30 / 12.00 2.14 /  2.80 
y-axis  7.46 /  6.72 0.70 / 0.60 25.30 / 22.70 5.80 / 5.92  9.27 /  7.41 0.70 / 0.60 31.00 / 29.40 7.37 /  6.65
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Mac OS X 10.5 (Apple Computer, Inc., Cu-
pertino, CA, USA). For the registration of 
MRI and PET images we used OsiriX (Osi-
riX Medical Image software, version 3.3, 
OsiriX Foundation, Geneva, Switzerland), 
available under a free software license. Osi-
riX implements manual landmark-based 
rigid registration of two image data sets, 
computing the best transform (three trans-
lational and three rotational degrees of 
freedom) to fit corresponding, user-se-
lected anatomical landmarks in a least 
squares sense. Registration between the 
transaxial PET images and the portal ve-
nous phase of the 3D GRE sequence was 
performed by two physicians resulting in 
two separate fused datasets (F1 and F2). 
Eight anatomical landmarks (the most 
cranial and most caudal located points of 
the liver, spleen and both kidneys) were 
marked in the portal venous phase of 
contrast enhanced MRI and in the low 
dose, non-contrast enhanced CT-com-
ponent of PET/CT (Fig. 2). These land-
marks were then copied from the CT-com-
ponent to the PET-component of PET/CT 
which was already registered with the CT-
component by hardware registration in the 
hybrid PET/CT-system. Due to the fact, 
that the PET- and the CT-component were 
already anatomically registered by the hy-
brid PET/CT-System, the landmarks could 
be copied one-to-one from the CT-compo-
nent to the PET-component. Finally, the 
PET data set was registered to the MRI data 
set by using the landmark-based algorithm, 
resampled onto a common grid and fused 
with the MRI data set.  
Data analysis and validation  
Two observers independently determined 
the x-, y- and z-coordinates of a second set 
of corresponding anatomical landmarks 
on the registered CT component of PET/
CT as well as on the 3D GRE sequence of 
MRI in each patient. The following land-
marks were used: the most anteriorly (ven-
trally) located point of the liver surface 
(called anterior liver border, AL); the point 
on the surface of the liver which was located 
most laterally at the level of the left portal 
vein (called lateral liver border, LL); origin 
of left portal vein (PV); the location of the 
celiac trunk at the level of the aortic origin 
(TC); the location of the right adrenal 
(RA); and if present, the center of the smal-
lest clearly detectable liver lesion (LE). At 
the level of the right adrenal gland, the in-
tersection of the lateral and medial limb 
was chosen as the reference point. If a liver 
lesion was present, the center of the smal-
lest lesion detectable on both studies was 
chosen as reference point. All anatomical 
landmarks used for data validation are 
shown in Figure 3.  
Coordinates of all these points were 
noted and the absolute distance between 
corresponding points in X-, Y- and Z- axis 
were determined separately. Additionally, 
Fig. 4 Patient (age: 44 years) with liver metastasis of colorectal carcinoma: ceMRI (a) and PET (b) after 
registration. PET/MR fusion (c) was graded comparable to hybrid PET/CT fusion (e) (grade 3). 
Fig. 5  
Fusions, which were 
subjectively rated to 
be poorly fused also 
showed a higher 
degree of objective 
registration error. 
Mean errors of regis-
tration are listed for 
each case and each 
observer. 
© Schattauer 2010 Nuklearmedizin 3/2010
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the Euclidean distance (D) between those 
chosen points in the two data sets was cal-
culated using the following equation, 
where p and q represent the coordinates of 
points P and Q:  
 
 
  
In addition, each observer separately as-
sessed the quality of image fusion on a 
3-point scale (1 poorly fused; 2 satisfactory 
fused; 3 correctly fused). Finally, each PET/
MR fusion was compared to integrated 
PET/CT fusion on a 3-point scale for image 
quality with regard to diagnostic purposes 
(1 worse than PET/CT and not diagnostic; 
2 worse than PET/CT but diagnostic; 3 
equal to PET/CT). Observers were asked to 
concentrate on the accuracy of the align-
ment in the region of the liver, of the kid-
neys and where available in the region of 
liver lesions.  
Bland-Altman analysis for inter-observer 
agreement was used to assess differences in 
measurements with the mean of observa-
tions (23, 24). The differences in measure-
ments were plotted against their means. The 
mean of the differences between values pro-
vided a measure of the bias or systematic 
error between measurements of both ob-
servers. The SD of the differences repre-
sented the variability between the tech-
niques, with bias of plus or minus 1.96 (SD) 
denoting the limits of agreement. Inter-ob-
server agreement was assessed for each of the 
fused datasets (F1 and F2) separately.  
Results 
Mean time of image registration and fusion 
was less than 2 minutes (mean, 2.0 ± 0.4 
minutes; range, 1.4–2.9 minutes for F1, and 
1.4 ± 0.3 minutes; range, 0.9–2.2 minutes 
for F2) including identifying the land-
marks.  
The anterior liver border was not access-
ible for measurement in 7/60 (11.7%), the 
lateral liver border in 4/60 (6.7%), the celiac 
trunk in 14/60 (23.3%) and the right adren-
al gland in 2/60 (3.3%) of patients. The ori-
gin of the left portal vein was visualized and 
accessible for measurement in all cases. 
When averaging the distances as 
measured by R1 and R2, the percentage of 
lesions misregistered by less than 10 mm 
were 95.1% and 91.0% in the x-axis, 86.7% 
and 86.1% in y-axis, 85.7% and 86.1% in 
z-axis and 60.8% and 60.3% in absolute 
distance. For R1 and R2, 83.2% and 82.9% 
of errors in absolute distance, respectively 
were smaller than 15 mm.  
Objective registration assessment 
showed mean errors of all registered ana-
tomical points of 2.4–6.3 mm in x-axis 
(mean R1 3.6 mm; R2 4.6 mm), 2.3–9.3 
mm in y-axis (mean 5.1 mm; 5.5 mm) and 
3.3–12.0 mm in z-axis (mean 5.9 mm; 5.9 
mm. The mean error in 3-dimensional dis-
tances between points was 6.0–16.8 mm 
(mean 9.9 mm; 10.6 mm) (Tab. 1). 
In visual assessment, most fusions were 
graded to be satisfactory or correctly fused: 
R1, R2: grade 3, 11/30 (36.7%), 22/30 
(73.3%); grade 2, 13/30 (43.3%), 8/30 
(26.7%); grade 1, 6/30 (20%), 0/30 (0%). 
Fusions were mostly comparable to hybrid 
PET/CT fusions (Fig. 4). Fusions, which 
were rated to be poorly fused also showed a 
higher degree of registration error (Fig. 
5). All of the registrations were defined as 
“diagnostic” by both observers (Tab. 2). 
Even if an image fusion showed an objec-
tively larger misregistration, observers were 
able to mentally assign the focus of FDG-
uptake to the corresponding liver lesion on 
CT (Fig. 6) and therefore judging the 
study as diagnostic.  
Bland-Altman analysis revealed small li-
mits of agreement for measurement of regis-
tration errors for F1 (i. e. AL 1.2 ± 7.0 mm; LL 
Tab. 2 Results of visual assessment
fusion  
quality 
observer 1 
mean SD 1 2 3 
in general* 2.17 0.75 6  
(20%) 
13  
(43.3%) 
11  
(36.7%) 
compared to  
hybrid PET/CT** 
2.40 0.50 0 18  
(60%) 
12  
(40%) 
*1: poor; 2: satisfactory; 3: correct; **1: worse, not diagnostic; 2: worse, diagnostic;  
3: equal to hybrid PET/CT; SD: standard deviation 
observer 2 
mean 
2.73 
2.60 
SD 
0.45 
0.50 
1 
0 
0 
2 
8  
(27%) 
12  
(40%) 
3 
22  
(73.3%) 
18  
(60%) 
Fig. 6 Patient (age: 62 years) with liver metastasis of colon carcinoma: ceMRI (a) and PET (b) after reg-
istration. PET/MR-fusion (c) with misregistration of SUV-uptake (arrowhead) and morphologic correlate 
of liver metastasis (arrow). Fusion is worse than hybrid PET/CT-fusion (d) but still diagnostic (grade 2). 
In addition benign liver cysts are noted in liver segments II and IVa. 
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2.1 ± 5.1 mm; PV 2.2 ± 3.2 mm; TC –2.9 ± 6.7 
mm; RA 0.6 ± 3.6 mm; LE 0.3 ± 3.6 mm) as 
well as for F2 (i.e. AL –5.3 ± 7.5 mm; LL 
–2.6 ± 6.7 mm; PV –0.6 ± 3.6 mm; TC 
–1.4 ± 8.9 mm; RA –2.1 ± 4.5 mm; LE 
–2.2 ± 3.9 mm). Also, mean differences be-
tween the measurements of both observers 
were minimal (i.e. AL –2.5 ± 7.9 mm; LL 
–0.4 ± 6.4 mm; PV 0.9 ± 3.6 mm; TC 
–2.2 ± 7.6 mm; RA –0.4 ± 4.1 mm; LE 
–0.8 ± 3.9 mm) (Fig. 7). 
Discussion 
This study demonstrates the feasibility to 
obtain reasonably accurate anatomical 
fusion images of PET and MRI of the upper 
abdomen by using the low dose CT-
 component of hybrid PET/CT and ceMRI 
even without the use of prerequisites such 
as immobilization in a vacuum mattress 
(25) or the application of external markers 
(26). 
Whereas accurate hardware-based regis-
tration of FDG-PET and CT data is cur-
rently standard of care for all anatomical 
body regions, there is less experience with 
registration of FDG-PET and MRI data sets 
in body imaging. While the accuracy and 
clinical value of PET/MRI-registration in 
the brain has been extensively validated 
(27–34), reports on the image fusion of 
FDG-PET and MRI data in the abdomen are 
rare. With regard to malignancies of the liver 
and pancreas, functional information de-
rived from PET may provide useful informa-
tion about the presence and suspected ma-
lignancy of a lesion as well as assessment of 
therapy. Presence or absence of FDG-activ-
ity may improve the level of confidence in 
determining the malignancy of a liver lesion 
of unclear origin and thereby help for stag-
ing and restaging of the tumour.  
The validation of PET/MRI registration 
techniques for clinical applications re-
mains particularly challenging, because 
each image type and organ requires separ-
ate evaluation of achievable accuracy (7). 
Whereas the brain is encased by a rigid shell 
which does not change shape or size be-
tween different imaging studies, the organs 
in the upper abdominal region are subject 
to breathing-dependent movement and de-
formation (35) . 
Using data from 30 patients, we studied 
the anatomical accuracy of rigid PET/MRI 
registration provided by an open-source 
software tool. For this purpose, we 
measured the absolute distances of well-de-
fined and reproducible anatomical land-
marks in MRI and the CT component of 
hybrid PET/CT.  
Recently, Lemke et al. published data of 
59 patients in which software-based image 
fusion of PET and unenhanced T1- and T2 
weighted and contrast media enhanced 
MRI (20) was performed in various ana-
tomical regions including the abdomen. As 
in our study, mainly contrast enhanced 
T1-weighted sequences were used for 
image fusion. The authors concluded that 
Fig. 7 Interreader reliability by Bland-Altman analysis: X-axis represents 
mean error of registration measured by R1 and R2 for each landmark. Y-axis 
represents the difference in errors measured by R1 and R2 for each landmark. 
Results are subdivided for cases registered by the two physicians (Fusion 1 
and Fusion 2), respectively. (AL: anterior liver border; LL: lateral liver border; 
TC: celiac trunc; PV: portal vein; RA: right adrenal gland; LL: liver lesion; R1: 
observer 1; R2: observer 2) 
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retrospective PET/MRI fusion is feasible al-
though evaluation did not include a 
quantitative validation of registration 
error. Ruf et al. (21) evaluated the impact of 
FDG-PET and MRI image fusion on the 
detection of pancreatic cancer. The authors 
concluded that PET/MRI fusion improved 
the anatomical assignment and interpre-
tation of FDG foci. Also in this study, 
contrast enhanced 3D GRE images ob-
tained in the portal venous phase were used 
for PET/MR image fusion. In accordance to 
these two studies, our study demonstrated 
that registration of FDG PET and MRI data 
sets is feasible without special adaptations 
in data acquisitions. As an adjunct to these 
aforementioned studies, our study assessed 
quantitatively the accuracy of image fusion 
in the upper abdomen using an open-
source software tool. The results of our 
study are comparable to the results ob-
tained for retrospective image registration 
of FDG-PET and CT data sets (36). Inagaki 
et al. (37) reported on the accuracy of retro-
spective PET/CT registration of the upper 
abdomen without external markers in 
seven patients. In the study of Inagaki et al. 
(37), the mean error was 3.4 mm in X-, 4.7 
mm in Y- and 9.2 mm in Z-axis. Similar re-
sults were also reported by Nakamoto et al. 
and Rizzo et al. (38, 39).  
Limitations 
Our study has several limitations. First, by 
using the CT-component of hybrid PET/
CT and therefore using an indirect regis-
tration technique, we propagate a potential 
misregistration emerging from the hybrid 
PET/CT registration into the retrospective 
registration process. However, misregis-
tration errors of hybrid PET/CT are gen-
erally small (40) and it has been shown that 
indirect PET/MR registration through the 
CT-part of hybrid PET/CT is subjectively 
more accurate than direct retrospective 
PET/MR registration (26). In the men-
tioned study, automatic voxel similarity 
based coregistration and external fiducial 
markers were used. A second limitation is 
that the mean time interval between PET/
CT and ceMRI was 11.3 days which may 
have influenced the misregistration error. 
On the other hand, the fact that retrospec-
tive fusion using the described method 
shows accurate registration even though 
registration of PET and MR was not 
planned at the time of data acquisition and 
therefore no special prerequisites in image 
acquisition protocols had been made can 
also be looked at as a strength of the de-
scribed fusion method.  
A third limitation of our study is a possi-
ble imprecision with regard to the manual 
localization of the anatomical landmarks 
chosen. Accuracy of image registration may 
be improved by using non-rigid registration 
but is more computationally expensive and 
questionably adds clinical value (41). 
 Finally, we only used the portal venous 
phase for image registration with the CT-
component of PET/CT as has been shown 
in other comparable studies (20, 21). How-
ever, the anatomical landmarks used for 
image registration (e. g. the upper and 
lower poles of the liver, kidneys and spleen) 
can also easily and accurately be detected in 
unenhanced MRI sequences.  
While integrated PET/MRI is currently 
being developed and first results have been 
published for head-only imaging systems 
(19), it has yet to be proven that there is 
substantial clinical value until first hybrid 
PET/MRI scanners are introduced into 
clinical routine. Meanwhile, in selected 
clinical cases, retrospective image fusion of 
PET- and MRI data can be done with sat-
isfying accuracy using routine protocols 
without taking special measures to pros-
pectively standardize imaging protocols. 
Since we performed image registration be-
tween PET and MRI in a limited anatomi-
cal volume (the upper abdomen), no state-
ment concerning the accuracy of whole 
body image fusion which is one of the ad-
vantages of hybrid PET/CT can be made. 
Finally, we did not investigate the diag-
nostic usefulness of PET/MRI in patients 
with malignancies of the upper abdomen. 
Conclusion 
Retrospective rigid image fusion of PET 
and MRI of the upper abdomen using an 
open-source freeware software is feasible 
without adaptation in image acquisition 
protocols and shows sub-centimeter regis-
tration errors in most cases. 
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